Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [PRO-Seq]

ABSTRACT: Acute myeloid leukemias (AMLs) have an overall poor prognosis and many high-risk cases co-opt stem cell gene regulatory programs, yet the mechanisms through which this occurs remain poorly understood. Increased expression of the stem cell transcription factor, MECOM, underlies one key driver mechanism in largely incurable AMLs. How MECOM results in such aggressive AML phenotypes remains unknown. To address existing experimental limitations, we engineered and applied targeted protein degradation with functional genomic readouts to demonstrate that MECOM promotes malignant stem cell-like states by directly repressing pro-differentiation gene regulatory programs. Remarkably and unexpectedly, a single node in this network, a MECOM-interacting regulatory element located 42 kb downstream of the myeloid differentiation regulator CEBPA is both necessary and sufficient for MECOM-driven leukemogenesis. Importantly, targeted activation of this regulatory element promotes differentiation of these aggressive AMLs and reduces leukemia burden in vivo, suggesting a broadly applicable differentiation-based approach for improving therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE284556 | GEO | 2025/09/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [RNA-Seq]

Project description:Acute myeloid leukemias (AMLs) have an overall poor prognosis and many high-risk cases co-opt stem cell gene regulatory programs, yet the mechanisms through which this occurs remain poorly understood. Increased expression of the stem cell transcription factor, MECOM, underlies one key driver mechanism in largely incurable AMLs. How MECOM results in such aggressive AML phenotypes remains unknown. To address existing experimental limitations, we engineered and applied targeted protein degradation with functional genomic readouts to demonstrate that MECOM promotes malignant stem cell-like states by directly repressing pro-differentiation gene regulatory programs. Remarkably and unexpectedly, a single node in this network, a MECOM-interacting regulatory element located 42 kb downstream of the myeloid differentiation regulator CEBPA is both necessary and sufficient for MECOM-driven leukemogenesis. Importantly, targeted activation of this regulatory element promotes differentiation of these aggressive AMLs and reduces leukemia burden in vivo, suggesting a broadly applicable differentiation-based approach for improving therapy.

2025-09-02 | GSE284558 | GEO

CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [ChIP-Seq]

2025-09-02 | GSE284555 | GEO

CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [ATAC-Seq]

2025-09-02 | GSE284553 | GEO

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia [4C-Seq]

Project description:The transcription factor MECOM, located at 3q26, is essential for hematopoietic stem cells (HSCs) in healthy individuals. Enhancer translocations, due to 3q26 rearrangements, drive out-of-context MECOM expression in an aggressive subtype of acute myeloid leukemia (AML). Aberrantly expressed MECOM is essential for the survival and immature phenotype of these leukemia cells. Direct depletion of MECOM using an endogenous auxin-inducible degron immediately upregulates expression of myeloid differentiation factor CEBPA. MECOM depletion is also accompanied by a severe loss of CD34 expression and gain of mature myeloid cell surface marker CD15. MECOM exerts its inhibitory effect on differentiation by binding to the +42kb CEBPA enhancer, which is required for neutrophil development. This is partially dependent on the interaction between MECOM and its essential co-repressor CTBP2, a potential target in this type of AML. We demonstrate that CEBPA overexpression can bypass the MECOM-mediated block of differentiation. In addition, AML patients with MECOM overexpression through enhancer hijacking show significantly reduced CEBPA. Our study provides insight into the mechanism by which MECOM maintains the stem cell state in AML. Furthermore, CEBPA levels are an important read-out for successful targeting of MECOM in 3q26-rearranged AML.

2025-02-01 | GSE285798 | GEO

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia [SLAM-seq]

2025-02-01 | GSE285803 | GEO

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia [ChIP-seq]

2025-02-01 | GSE285800 | GEO

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia [ATAC-seq]

2025-02-01 | GSE285799 | GEO

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia [RNA-seq]

2025-02-01 | GSE286032 | GEO

The neuronal homeobox transcription factor HMX3 is a crucial vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia [RNAseq_CD34_HSPC_ectopic_HMX3]

Project description:The KMT2A::MLLT3 fusion protein causes acute myeloid leukemia (AML) by activating the oncogenic transcription factor MECOM. However, MECOM expression occurs only in half of the cases. By integrating gene expression and enhancer activity data from patient cells, we identified neuronal homeobox transcription factor HMX3 as cell fate determining factor in MECOM-negative KMT2A::MLLT3 AML. HMX3 expression associated with younger age and KMT2A-rearranged leukemia in large AML cohorts (p<0.002). It was absent in other major genetic risk groups and healthy blood cells. Transcriptomic analyses revealed that HMX3 drives cancer-associated E2F, MYC, and cell cycle gene programs. Ectopic HMX3 expression completely inhibited monocytic but not granulocytic colony formation of healthy CD34+ cord blood cells. Its silencing in KMT2A::MLLT3 AML cell lines and patient cells resulted in cell cycle arrest, monocytic differentiation, and apoptosis. Thus, HMX3 is a leukemia-specific vulnerability that enhances proliferation and blocks differentiation of MECOM-negative KMT2A::MLLT3 leukemia.

2024-12-13 | GSE242956 | GEO

The neuronal homeobox transcription factor HMX3 is a crucial vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia [RNAseq_MOLM13_HMX3_KD]

2024-12-13 | GSE242962 | GEO